The molecular pathology of cutaneous melanoma

Cancer Biomarkers

Volumn 9, Issue 1-6, 2011, Pages 267-286

  Bogenrieder, Thomas ^a   Herlyn, Meenhard ^b  

^a BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^b WISTAR INSTITUTE   (United States)

Author keywords

Apaf1; Bcl2; BRAF; CDKs; cell cycle; ckit; cmet; cmyc; cyclins; HGF; MAPK pathway; Melanoma; Notch; p14ARF; p16INK4A; PI3K AKTpathway; pRb pathway; PTEN; Ras; SCF

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; B RAF KINASE; CYCLIN A; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MAMMALIAN TARGET OF RAPAMYCIN; MELANIN; MELANOCORTIN 1 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; RAS PROTEIN; SCATTER FACTOR; STEM CELL FACTOR;

ANTISENSE THERAPY; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; DRUG EFFICACY; GENE MUTATION; HUMAN; MELANOMA; NEVUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL CYCLE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 82955249988     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2011-0164     Document Type: Article

References (124)

1. A. M. DeLuca, A. Srinivas and A. Alani, BRAF kinase in melanoma development and progression, Expert Rev Mol Med 10 (2008), e6.
2. K. S. Smalley and M. Herlyn, Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy, Int J Cancer 124 (2009), 1245-1250.
3. K. S. Smalley, Understanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy, J Invest Dermatol (2009).
4. K. S. Smalley, K. L. Nathanson and K. T. Flaherty, Genetic subgrouping of melanoma reveals new opportunities for targeted therapy, Cancer Res 69 (2009), 3241-3244.
5. A. Sekulic, P. Jr. Haluska, A. J. Miller et al. , Malignant melanoma in the 21st century: the emerging molecular landscape, Mayo Clin Proc 83 (2008), 825-846.
6. E. Bajetta, V. M. Del, C. Bernard-Marty et al. , Metastatic melanoma: chemotherapy, Semin Oncol 29 (2002), 427-445.
7. L. Serrone, M. Zeuli, F. M. Sega et al. , Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview, J Exp Clin Cancer Res 19 (2000), 21-34.
8. W. Sun and L. M. Schuchter, Metastatic melanoma, Curr Treat Options Oncol 2 (2001), 193-202.
9. L. M. Haass and M. Herlyn, Normal human melanocyte homeostasis as a paradigm for understanding melanoma, J Investig Dermatol Symp Proc 10 (2005), 153-163.
10. N. K. Haass, K. S. Smalley, L. Li et al. , Adhesion, migration and communication in melanocytes and melanoma 56, Pigment Cell Res 18 (2005), 150-159.
11. T. Bogenrieder, T. Elder and M. Herlyn, Molecular and cellular Biology, in: Cutaneous Melanoma, C. M. Balch, A. N. Houghton, A. J. Sober and S. J. Soong, eds, 2003, p. 751.
12. K. S. Smalley, M. Lioni andM. Herlyn, Targeting the stromal fibroblasts: a novel approach to melanoma therapy, Expert Rev Anticancer Ther 5 (2005), 1069-1078.
13. M. Thompson, M. Scolyer and M. Kefford, Cutaneous melanoma, Lancet 365 (2005), 687-701.
14. M. Li, A. Sanki, A. Karim et al. , The role of cell cycle regulatory proteins in the pathogenesis of melanoma, Pathology (Phila) 38 (2006), 287-301.
15. M. Malumbres, P. Pevarello, M. Barbacid et al. , CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 29 (2008), 16-21.
16. M. Malumbres and M. Barbacid Cell cycle, CDKs and cancer: a changing paradigm, Nat Rev Cancer 9 (2009), 153-166.
17. G. J. Walker, J. F. Flores, J. F. Glendening et al. , Virtually 100% of melanoma cell lines harbor alterations at the DNA levelwithinCDKN2A, CDKN2B, or one of their downstream targets, Genes Chromosomes Cancer 22 (1998), 157-163.
18. J. Bartkova, J. Lukas, J. Guldberg et al. , The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis, Cancer Res 56 (1996), 5475-5483.
19. J. A. Curtin, J. Fridlyand, T. Kageshita et al. , Distinct sets of genetic alterations in melanoma, N Engl J Med 353 (2005), 2135-2147.
20. T. Reed, F. Loganzo, Jr. , F. Shea, Jr. et al. , Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression, Cancer Res 55 (1995), 2713-2718.
21. D. Polsky, A. Z. Young, A. Z. Busam et al. , The transcriptional repressor of p16/Ink4a, Id1, is up-regulated in early melanomas, Cancer Res 61 (2001), 6008-6011.
22. A. Z. Florenes, A. Z. Faye, G. M. Maelandsmo et al. , Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma, Clin Cancer Res 6 (2000), 3614-3620.
23. G. M. Florenes, G. M. Maelandsmo, G. M. Kerbel et al. , Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival, Am J Pathol 153 (1998), 305-312.
24. J. Georgieva, P. Sinha and P. Schadendorf, Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions, J Clin Pathol 54 (2001), 229-235.
25. G. M. Maelandsmo, R. Holm, O. Fodstad et al. , Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions, Am J Pathol 149 (1996), 1813-1822.
26. D. Hanahan and R. A. Weinberg, The hallmarks of cancer, Cell 100 (2000), 57-70.
27. R. A. Hussein, A. K. Haemel and G. S. Wood, Apoptosis and melanoma: molecular mechanisms, J Pathol 199 (2003), 275-288.
28. M. S. Soengas and S. W. Lowe, Apoptosis and melanoma chemoresistance, Oncogene 22 (2003), 3138-3151.
29. S. W. Soengas, R. M. Alarcon, R. M. Yoshida et al. , Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition, Science 284 (1999), 156-159.
30. K. S. Smalley, K. S. Contractor, N. K. Haass et al. , An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells, Cancer Res 67 (2007), 209-217.
31. M. S. Soengas and S. W. Lowe, p53 and p73: seeing double? Nat Genet 26 (2000), 391-392.
32. M. R. Hussein, A. K. Haemel and G. S. Wood, Apoptosis and melanoma: molecular mechanisms, J Pathol 199 (2003), 275-288.
33. S. W. Lowe and A. W. Lin, Apoptosis in cancer, Carcinogenesis 21 (2000), 485-495.
34. K. Satyamoorthy, T. Bogenrieder and M. Herlyn, No longer a molecular black box-new clues to apoptosis and drug resistance in melanoma, Trends Mol Med 7 (2001), 191-194.
35. K. Satyamoorthy, N. H. Chehab, M. J. Waterman et al. , Aberrant regulation and function ofwild-type p53 in radioresistant melanoma cells, Cell Growth Differ 11 (2000), 467-474.
36. M. S. Soengas, P. Capodieci, D. Polsky et al. , Inactivation of the apoptosis effector Apaf-1 inmalignant melanoma, Nature 409 (2001), 207-211.
37. J. A. Bush and G. Li, The role of Bcl-2 family members in the progression of cutaneous melanoma, Clin Exp Metastasis 20 (2003), 531-539.
38. K. Yamamura, S. Kamada, S. Ito et al. , Accelerated disappearance of melanocytes in bcl-2-deficient mice, Cancer Res 56 (1996), 3546-3550.
39. C. A. Schmitt, C. T. Rosenthal and S. W. Lowe, Genetic analysis of chemoresistance in primary murine lymphomas, Nat Med 6 (2000), 1029-1035.
40. B. Jansen, H. Schlagbauer-Wadl, B. D. Brown et al. , bcl-2 antisense therapy chemosensitizes humanmelanoma in SCID mice, Nat Med 4 (1998), 232-234.
41. A. S. Dhillon, S. Hagan, O. Rath et al. ,MAP kinase signaling pathways in cancer, Oncogene 26 (2007), 3279-3290.
42. P. J. Roberts and C. J. Der, Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer, Oncogene 26 (2007), 3291-3310.
43. M. S. Brose, P. Volpe, M. Feldman et al. , BRAF and RAS mutations in human lung cancer and melanoma, Cancer Res 62 (2002), 6997-7000.
44. H. Davies, G. R. Bignell, C. Cox et al. , Mutations of the BRAF gene in human cancer, Nature 417 (2002), 949-954.
45. N. Dhomen and R. Marais, BRAF signaling and targeted therapies in melanoma, Hematol Oncol Clin North Am 23 (2009), 529-545.
46. P. T. Wan, M. J. Garnett, S. M. Roe et al. , Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, Cell 116 (2004), 855-867.
47. J. L. Maldonado, J. Fridlyand, H. Patel et al. , Determinants of BRAF mutations in primary melanomas, J Natl Cancer Inst 95 (2003), 1878-1890.
48. A. Weber, U. R. Hengge, D. Urbanik et al. , Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase inmalignant melanomas of the uvea, Lab Invest 83 (2003), 1771-1776.
49. M. T. Landi, J. Bauer, R. M. Pfeiffer et al. , MC1R germline variants confer risk for BRAF-mutant melanoma, Science 313 (2006), 521-522.
50. K. V. Bhatt, L. S. Spofford, G. Aram et al. , Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling, Oncogene 24 (2005), 3459-3471.
51. P. M. Pollock, U. L. Harper, K. S. Hansen et al. , High frequency of BRAF mutations in nevi 308, Nat Genet 33 (2003), 19-20.
52. P. Uribe, I. I. Wistuba and S. Gonzalez, BRAF mutation: a frequent event in benign, atypical, andmalignantmelanocytic lesions of the skin, Am J Dermatopathol 25 (2003), 365-370.
53. R. Kumar, S. Angelini, E. Snellman et al. , BRAF mutations are common somatic events in melanocytic nevi, J Invest Dermatol 122 (2004), 342-348.
54. P. Uribe, L. Andrade and S. Gonzalez, Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi, J Invest Dermatol 126 (2006), 161-166.
55. C. Michaloglou, L. C. Vredeveld and M. S. Soengas et al. , BRAFE600-associated senescence-like cell cycle arrest of human naevi, Nature 436 (2005), 720-724.
56. N. K. Haass, K. Sproesser, T. K. Nguyen et al. , The mitogenactivated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel, Clin Cancer Res 14 (2008), 230-239.
57. K. S. Smalley and M. Herlyn, Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics, Ann N Y Acad Sci 1059 (2005), 16-25.
58. M. Shinozaki, A. Fujimoto, D. L. Morton et al. , Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas, Clin Cancer Res 10 (2004), 1753-1757.
59. R. Kumar, S. Angelini, K. Czene et al. , BRAF mutations in metastatic melanoma: a possible association with clinical outcome, Clin Cancer Res 9 (2003), 3362-3368.
60. M. Kono, I. S. Dunn, P. J. Durda et al. , Role of the mitogenactivated protein kinase signaling pathway in the regulation of human melanocytic antigen expression, Mol Cancer Res 4 (2006), 779-792.
61. H. Sumimoto, F. Imabayashi, T. Iwata et al. , The BRAFMAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells, J Exp Med 203 (2006), 1651-1656.
62. C. Montagut, S. V. Sharma, T. Shioda et al. , Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma, Cancer Res 68 (2008), 4853-4861.
63. N. Dumaz, R. Hayward, J. Martin et al. , In melanoma, RASmutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling, Cancer Res 66 (2006), 9483-9491.
64. J. P. Arnault, J. Wechsler, B. Escudier et al. , Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib, J Clin Oncol 27 (2009), e59-e61.
65. K. Ehrenreiter, F. Kern, V. Velamoor et al. , Raf-1 addiction in Ras-induced skin carcinogenesis, Cancer Cell 16 (2009), 149-160.
66. L. A. Fecher, S. D. Cummings, M. J. Keefe et al. , Toward a molecular classification of melanoma, J Clin Oncol 25 (2007), 1606-1620.
67. V. Gray-Schopfer, C. Wellbrock and R. Marais, Melanoma biology and new targeted therapy, Nature 445 (2007), 851-857.
68. W. M. Lin, A. C. Baker, R. Beroukhim et al. , Modeling genomic diversity and tumor dependency in malignant melanoma, Cancer Res 68 (2008), 664-673
69. X. P. Zhou, O. Gimm, H. Hampel et al. , Epigenetic PTEN silencing in malignant melanomas without PTEN mutation, Am J Pathol 157 (2000), 1123-1128.
70. J. M. Stahl, A. Sharma, M. Cheung et al. , Deregulated Akt3 activity promotes development ofmalignantmelanoma, Cancer Res 64 (2004), 7002-7010.
71. H. Tsao, V. Goel, H. Wu et al. , Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma, J Invest Dermatol 122 (2004), 337-341.
72. K. Satyamoorthy, G. Li, B. Vaidya et al. , Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways, Cancer Res 61 (2001), 7318-7324.
73. D. P. Brazil, J. Park and B. A. Hemmings, PKB binding proteins. Getting in on the Akt, Cell 111 (2002), 293-303.
74. B. C. Bastian, P. E. LeBoit, H. Hamm et al. , Chromosomal gains and losses in primary cutaneousmelanomas detected by comparative genomic hybridization, Cancer Res 58 (1998), 2170-2175.
75. M. A. Davies, K. Stemke-Hale, C. Tellez et al. , Anovel AKT3 mutation in melanoma tumours and cell lines, Br J Cancer 99 (2008), 1265-1268.
76. G. P. Robertson, Functional and therapeutic significance of Akt deregulation inmalignant melanoma, Cancer Metastasis Rev 24 (2005), 273-285.
77. M. Cheung, A. Sharma, S. V. Madhunapantula et al. , Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development, Cancer Res 68 (2008), 3429-3439.
78. D. Dankort, D. P. Curley, R. A. Cartlidge et al. , Braf(V600E) cooperates with Pten loss to induce metastatic melanoma, Nat Genet 41 (2009), 544-552.
79. K. S. Smalley and K. T. Flaherty, Integrating BRAF/MEK inhibitors into combination therapy for melanoma, Br J Cancer 100 (2009), 431-435.
80. T. Eisen, T. Ahmad, K. T. Flaherty et al. , Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis, Br J Cancer 95 (2006), 581-586.
81. K. S. Smalley, M. Lioni, P. M. Dalla et al. , Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas, Mol Cancer Ther 7 (2008), 2876-2883.
82. K. S. Smalley, V. K. Sondak and J. S. Weber, c-KIT signaling as the driving oncogenic event in sub-groups of melanomas, Histol Histopathol 24 (2009), 643-650.
83. P. G. Natali, M. R. Nicotra, A. B. Winkler et al. , Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor, Int J Cancer 52 (1992), 197-201.
84. J. M. Grichnik, Kit and melanocyte migration, J Invest Dermatol 126 (2006), 945-947.
85. S. Huang,M. Luca,M. Gutman et al. , Enforced c-KIT expression renders highlymetastatic humanmelanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential, Oncogene 13 (1996), 2339-2347.
86. J. A. Curtin, K. Busam, D. Pinkel et al. , Somatic activation of KIT in distinct subtypes of melanoma, J Clin Oncol 24 (2006), 4340-4346.
87. R. S. Rivera, H. Nagatsuka, M. Gunduz et al. , C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma, Virchows Arch 452 (2008), 27-32.
88. C. R. Antonescu, K. J. Busam, T. D. Francone et al. , L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition, Int J Cancer 121 (2007), 257-264.
89. K. S. Smalley, R. Contractor, T. K. Nguyen et al. , Identification of a novel subgroup of melanomas with KIT/cyclindependent kinase-4 overexpression, Cancer Res 68 (2008), 5743-5752.
90. N. Puri, S. Ahmed, V. Janamanchi et al. , c-Met is a potentially new therapeutic target for treatment of human melanoma, Clin Cancer Res 13 (2007), 2246-2253.
91. G. Li, H. Schaider, K. Satyamoorthy et al. , Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development, Oncogene 20 (2001), 8125-8135.
92. T. Kunisada, H. Yamazaki, T. Hirobe et al. , Keratinocyte expression of transgenic hepatocyte growth factor affects melanocyte development, leading to dermal melanocytosis, Mech Dev 94 (2000), 67-78.
93. R. Halaban, J. S. Rubin, Y. Funasaka et al. , Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells, Oncogene 7 (1992), 2195-2206.
94. F. P. Noonan, J. Dudek, G. Merlino et al. , Animal models of melanoma: an HGF/SF transgenic mouse model may facilitate experimental access to UV initiating events, Pigment Cell Res 16 (2003), 16-25.
95. T. Otsuka, H. Takayama, R. Sharp et al. , c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype, Cancer Res 58 (1998), 5157-5167.
96. M. Y. Hsu, F. Meier and M. Herlyn, Melanoma development and progression: a conspiracy between tumor and host, Differentiation 70 (2002), 522-536.
97. P. G. Natali, M. R. Nicotra, M. F. Di Renzo et al. , Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression, Br J Cancer 68 (1993), 746-750.
98. J. Cruz, J. S. Reis-Filho, P. Silva et al. , Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas, Oncology 65 (2003), 72-82.
99. F. P. Noonan, T. Otsuka, S. Bang et al. , Accelerated ultraviolet radiation-induced carcinogenesis in hepatocyte growth factor/scatter factor transgenic mice, Cancer Res 60 (2000), 3738-3743.
100. A. J. Ramsden, R. Grover, J. Chana et al. , A prospective analysis of c-myc oncoprotein levels as a prognostic marker in malignant melanoma, J Plast Reconstr Aesthet Surg 60 (2007), 626-630.
101. H. Wu, V. Goel and F. G. Haluska, PTEN signaling pathways in melanoma, Oncogene 22 (2003), 3113-3122.
102. D. A. Ross, J. H. Laing, R. Sanders et al. , Long term follow-up of c-myc, p53 and proliferation measurements in malignant melanoma, Eur J Surg Oncol 32 (2006), 80-84.
103. H. Schlagbauer-Wadl, M. Griffioen, E. A. van et al. , Influence of increased c-Myc expression on the growth characteristics of human melanoma, J Invest Dermatol 112 (1999), 332-336.
104. D. Zhuang, S. Mannava, V. Grachtchouk et al. , C-MYC overexpression is required for continuous suppression of ncogene-induced senescence in melanoma cells, Oncogene 27 (2008), 6623-6634.
105. G. D. Hurlbut, M. W. Kankel, R. J. Lake et al. , Crossing paths with Notch in the hyper-network, Curr Opin Cell Biol 19 (2007), 166-175.
106. E. J. Allenspach, I. Maillard, J. C. Aster et al. , Notch signaling in cancer, Cancer Biol Ther 1 (2002), 466-476.
107. C. C. Pinnix and M. Herlyn, The many faces of Notch signaling in skin-derived cells, Pigment Cell Res 20 (2007), 458-465.
108. B. J. Nickoloff, M. J. Hendrix, P. M. Pollock et al. , Notch and NOXA-related pathways in melanoma cells, J Investig Dermatol Symp Proc 10 (2005), 95-104.
109. M. Nicolas, A. Wolfer, K. Raj et al. , Notch1 functions as a tumor suppressor in mouse skin, Nat Genet 33 (2003), 416-421.
110. K. Balint, M. Xiao, C. C. Pinnix et al. , Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression, Clin Invest 115 (2005), 3166-3176.
111. K. Hoek, D. L. Rimm, K. R. Williams et al. , Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas, Cancer Res 64 (2004), 5270-5282.
112. C. C. Pinnix, J. T. Lee, Z. J. Liu et al. , Active Notch1 confers a transformed phenotype to primary human melanocytes, Cancer Res 69 (2009), 5312-5320.
113. C. L. Curry, L. L. Reed, T. E. Golde et al. , Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells, Oncogene 24 (2005), 6333-6344.
114. J. Z. Qin, L. Stennett, P. Bacon et al. , p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas, Mol Cancer Ther 3 (2004), 895-902.
115. B. Bedogni, J. A. Warneke, B. J. Nickoloff et al. , Notch1 is an effector of Akt and hypoxia in melanoma development, J Clin Invest 118 (2008), 3660-3670.
116. D. B. Solit, L. A. Garraway, C. A. Pratilas et al. , BRAF mutation predicts sensitivity to MEK inhibition, Nature 439 (2006), 358-362.
117. K. S. Smalley, N. K. Haass, P. A. Brafford et al. , Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases, Mol Cancer Ther 5 (2006), 1136-1144.
118. E. R. Sauter, U. C. Yeo, S. A. von et al. , Cyclin D1 is a candidate oncogene in cutaneous melanoma, Cancer Res 62 (2002), 3200-3206.
119. L. A. Garraway, H. R. Widlund, M. A. Rubin et al. , Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma, Nature 436 (2005), 117-122.
120. G. M. Kraehn, J. Utikal, M. Udart et al. , Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases, Br J Cancer 84 (2001), 72-79.
121. D. A. Ross and G. D. Wilson, Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma, Br J Surg 85 (1998), 46-51.
122. E. Sharpless and L. Chin, The INK4a/ARF locus and melanoma, Oncogene 22 (2003), 3092-3098.
123. J. M. Stahl, M. Cheung, A. Sharma et al. , Loss of PTEN promotes tumor development in malignant melanoma, Cancer Res 63 (2003), 2881-2890.
124. O. Straume and L. A. Akslen, Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma, Int J Cancer 74 (1997), 535-539.